Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Overview
Listen
Lyrics
People also search for
Lyrics
Well, I've walked these streets
A virtual stage, it seemed to me
Makeup on their faces
Actors took their places next to me
Well, I've walked these streets
In a carnival, of sights to see
All the cheap thrill seekers vendors and the dealers
They crowded around me
Have I been blind have I been lost
Inside myself and my own mind
Hypnotized, mesmerized by what my eyes have seen?
Well, I've walked these streets
In a spectacle of wealth and poverty
In the diamond markets the scarlet welcome carpet
That they just rolled out for me
And I've walked these streets
In the madhouse asylum they can be
Where a wild-eyed misfit prophet
On a traffic island stopped and he raved of saving me
Have I been blind, have I been lost
Inside myself and my own mind
Hypnotized, mesmerized by what my eyes have seen
Have I been wrong, have I been wise
To shut my eyes and play along
Hypnotized, paralyzed by what my eyes have found
By what my eyes have seen
What they have seen?
Have I been blind
Have I been lost
Have I been wrong
Have I been wise
Have I been strong
Have I been hypnotized, mesmerized by what my eyes have found
In that great street carnival
Rollin', rollin', rollin'
Rollin', rollin', rollin'
Rollin', rollin', rollin'
Rollin', rollin', rollin'
Rawhide!
Cut 'em out
(Ride 'em in!)
Ride 'em in
(Cut em' out!)
Cut 'em out
Ride 'em in
Rawhide!
Keep movin', movin', movin'
Though they're disaprovin'
Keep them doggies movin'
Rawhide
Don't try to understand 'em
Just rope, throw, and brand 'em
Soon we'll be livin' high and wide
Rawhide!!!
Epiphany
Welcome to the planet
Welcome to existence
Everyone's here
Everyone's here
Everybody's watching you now
Everybody waits for you now
What happens next?
What happens next?
I dare you to move
I dare you to move
I dare you to lift yourself up off the floor
I dare you to move
I dare you to move
Like today never happened
Today never happened before
Epiphany
Some have no faith.
The word "epiphany" descends from the ancient Greek ?p?f?´?e?? (epipháneia), meaning a "manifestation or appearance."
The word is built from the Greek words "pha" (to shine), "phanein" (to show, to cause to shine), and "epiphanein" (to manifest, to bring to light).
In ancient Greek usage, the term often describes the visible manifestation of a god.
SFIO
Hurry up and wait.
Is this the real deal?
Only time will tell.
Diamond Hands!!
Time and Money.
That's Life?
We need to learn to share these God given "commodities".
Cannabis on an Even Exchange, would be a good start.
The fruits of this plant WILL heal the nations once more.
Cause it's a bitter sweet symphony, that's life
Tryin' to make ends meet, you're a slave to money then you die
I'll take you down the only road I've ever been down
You know the one that takes you to the places where all the veins meet, yeah
No change, I can change, I can change, I can change
But I'm here in my mold, I am here in my mold
But I'm a million different people from one day to the next
I can't change my mold, no, no, no, no, no
(Have you ever been down?)
Well, I've never prayed, but tonight I'm on my knees, yeah
I need to hear some sounds that recognize the pain in me, yeah
I let the melody shine, let it cleanse my mind, I feel free now
But the airwaves are clean and there's nobody singing to me now
No change, I can change, I can change, I can change
But I'm here in my mold, I am here in my mold
And I'm a million different people from one day to the next
I can't change my mold, no, no, no, no, no
(Have you ever been down?)
I can't change, don't you know?
I can't change it
'Cause it's a bitter sweet symphony, that's life
Tryin' to make ends meet, tryin' to find some money then you die
I'll take you down the only road I've ever been down
You know the one that takes you to the places where all the veins meet, yeah
You know, I can change, I can change, I can change, I can change
But I'm here in my mold, I am here in my mold
And I'm a million different people from one day to the next
I can't change my mold, no, no, no, no, no
I can't change my mold, no, no, no, no, no
I can't change my mold, no, no, no, no, no
It's just sex and violence, melody and silence
It's just I can't change my violence, melody and violence
I'll take you down the only road I've ever been down (sex and violence, melody and silence)
It's just I can't change my violence, melody and silence
I'll take you down the only road I've ever been down (sex and violence, melody and silence)
Been down
Ever been down
Ever been down
Ever been down
Have you ever been down?
Have you ever been down?
Have you ever been down?
Songwriters: Mick Jagger / Keith Richards
The market is FAIR!
All giving and all taking!
I'm guessing 8 cents for your purchase when you can buy again.
Good luck on your investment.
I once rolled a neverending joint.
Anything is possible!
I am still learning.
ENDO
It's all about Epiphany
Epiphany - a manifestation of a divine or supernatural being.
Diamond hands, that's a new one for me.
I like it!
I will hold for diamonds!
Epiphany!
Bringing it all together!
A mighty task at hand!
This is their time to shine!
The fruits of this plant will heal the nations once more.
RIGHs UP
Opportunity abundant right now in the OTC.
Hopefully some will prevail and become real companies.
Good luck on your investment!
http://technisoil.com/
Does this have anything to do with CTLE?
I remember years back they were in the business of sand and gravel and nano tech.
I had an "epiphany" once, and in my never ending quest to understand it's meaning it led me to SFIO some 10 years ago. They were to make a cannabis smokeless, vaporless, full flavor, full spectrum, flavonoids, terpenes, thc, cbd, cbn etc. ,medical e-joint with nano technology.
Well we all know how that turned out.
And now we have Epiphany Cafe.
The Lord truly works in mysterious ways.
Who knows where this will lead me, but I will continue to hold for HIGHER pps.
Good luck on your investment
Jamaica partnership with Harvard Institute to help Island cannabis compete worldwide
BY EMMA SPEARS
ORIGINALLY PUBLISHED: SEP 30, 2019
Jamaica is poised to rake in billions as its local medical cannabis industry heats up
Jamaica is looking to gain a competitive edge in the worldwide cannabis market by partnering with the American Harvard International Phytomedicines and Medical Cannabis Institute (HIPI).
Megatron partners in marijuana-for-CTE research
?
MICHAEL ROTHSTEINESPN Staff WriterAug 15, 20194 Minute Read
?
Foxworth: Marijuana testing won't be a big issue in new CBA
Domonique Foxworth and Dan Orlovsky discuss the impact the new NFL CBA will have on younger players and the league's policy on marijuana.
Former Detroit Lions wide receiver Calvin Johnson and his business partner, ex-NFL lineman Rob Sims, have partnered with Harvard University to research the benefits of medical marijuana in the areas of chronic traumatic encephalopathy, more commonly known as CTE, and the management of pain.
Johnson and Sims co-own the cannabis company Primitive. They announced the partnership, which includes a six-figure donation with the option for future money, to the International Phytomedicines and Medical Cannabis Institute at Harvard during the Cannabis Capital Conference in Detroit on Thursday.
"We can be in position to develop a treatment for CTE," Sims told ESPN on Thursday night. "There's been suggestion that CBD [cannabidiol, a compound in cannabis] and stuff can help cognitive disease, and we think that potentially there could be a treatment going forward that we can produce."
Sims and Johnson were part of Harvard's Global Catalyst Health Summit in May, when they agreed to make the commitment to give research money and start a consortium with the brain-performance company NESTRE to work with the institute and Dr. Wilfred Ngwa. NESTRE has worked on brain training with NFL athletes, including former quarterback and current ESPN analyst Josh McCown later in his career.
As part of the partnership, Harvard will do medical research for Primitive, run clinical trials related to CTE and pain and also will provide quality assurance from Harvard Medical School for any products the company creates. As former NFL players, Sims and Johnson say they have researched studies on CTE and football that show the disease as prevalent among former players. CTE can be diagnosed only postmortem.
"As being former athletes, we know there's some sort of CTE or some sort of damage, 99% I think they say in the study," Sims said. "So that means I may be walking around with some form of it. It's really about the hope. Just providing hope, improving the game, making the game safer for former players after they are done.
"Really just being able to help people. I'm a second-generation NFL kid; both my father and father-in-law [played]. I've seen the good, the bad and the ugly of what it looks like when you're done playing ball. If we can help this facet of people suffering from CTE or other cognitive disease, that's the real goal here."
This is the beginning of what Johnson and Sims are hoping is a long-term partnership with the institute. If they are able to help people, they figure the business portion of it will follow.
"What our mission is going to be is just to improve quality of life," Sims said. "So, you know, with NESTRE and the brain training and the human optimization, we believe there's a way to continue to improve your brain function through working out.
"Then, from our position, with that data that we'll be able to gain, we believe that we can produce plant medicines, or cannabis, using nanotechnology to deliver payloads to areas where people would have symptoms of CTE, like mood and anxiety and memory loss. That's the goal in the end."
Sims said there isn't a set date for the clinical trials to begin, but he is hopeful they can start during the first quarter of 2020.
This is the latest business venture for Sims and Johnson, who started working together as a real estate company and also opened a consulting firm before choosing to go the cannabis route after Michigan legalized marijuana in November. Their first attempt to get a license was rejected by the state, but those issues have since been rectified, and their first cultivation facility is scheduled to open within the next month or so in Webberville, Michigan.
That's a long way from their beginnings, when they never imagined they would be partnered with Harvard.
"Never in a million years, man," Sims said. "I was trying to get Calvin to flip one or two houses with me two years ago, and then we ended up getting into cannabis real estate, and then we ended up getting into the licensing part of it, and now we're getting into the medicine part of it.
"So it's been quite a journey, and I'm just looking forward to the future."
The gift that keeps on giving!
The fruits of this plant will heal the nations once more.
#Get Dennis Rodman back to North Korea
Any moment now
In the soon there after
Hey $Pistol Pete!$
What is your guess on where CBIS will bottom out? Are you buying CBIS now? What is your opinion of CBIS?
Your thoughts would be appreciated
Cannabis is one of the primary plants the IPI will begin studying.
The IPI aims to apply the wealth of science and technology at Harvard and strategically partner it with other educational institutions and private industry to convert potential high-impact medicinal plants “to evidence-based pharmaceutical grade products for global health and economic development.”
Leading the effort is Professor Wil Ngwa, who is director of the Global Health Catalyst at Brigham and Women's Hospital and Dana-Farber Cancer Institute, both affiliated with Harvard Medical School. Ngwa sees the collaborations as a key to providing focused and detailed research into the medicinal qualities of the cannabis plant.
“You need the critical mass of people coming together, and I think that Harvard provides that platform,” he said.
Seed funding for the initiative was provided by the Brigham and Women's Hospital and Dana-Farber Cancer Institute, and it includes funding support and sponsored research agreements with industry partners.
While initial commitments from the launch already have reached $6 million, more funds are expected from ongoing partnership discussions, according to Lydia Asana, Ph.D., coordinator for the Harvard Global Health Catalyst Summit. So far, the focus of the Global Health Catalyst has been research into cancer and non-communicable diseases, but in the last few years researchers at the center developed an interest in pain management, Asana said.
Harvard Researchers To Explore Cannabis As Medicine For Less-Affluent Nations
WeedMaps News
BenzingaJuly 8, 2019, 1:01 PM CDT
By Don Jergler
A new collaborative institute aims to study cannabis as part of its mission to increase access to evidence-based plant medicine in poor and developing nations.
The International Phytomedicines Institute (IPI) at Harvard Medical School, was launched on May 26 during the 2019 Global Health Catalyst summit at Harvard Medical School, an annual conference focused primarily on reducing disparities to access to healthcare. Phytomedicine is a plant-based medicinal practice that utilizes plant materials for preventive and therapeutic purposes
Cannabis is one of the primary plants the IPI will begin studying.
The IPI aims to apply the wealth of science and technology at Harvard and strategically partner it with other educational institutions and private industry to convert potential high-impact medicinal plants “to evidence-based pharmaceutical grade products for global health and economic development.”
Leading the effort is Professor Wil Ngwa, who is director of the Global Health Catalyst at Brigham and Women's Hospital and Dana-Farber Cancer Institute, both affiliated with Harvard Medical School. Ngwa sees the collaborations as a key to providing focused and detailed research into the medicinal qualities of the cannabis plant.
“You need the critical mass of people coming together, and I think that Harvard provides that platform,” he said.
Seed funding for the initiative was provided by the Brigham and Women's Hospital and Dana-Farber Cancer Institute, and it includes funding support and sponsored research agreements with industry partners.
While initial commitments from the launch already have reached $6 million, more funds are expected from ongoing partnership discussions, according to Lydia Asana, Ph.D., coordinator for the Harvard Global Health Catalyst Summit. So far, the focus of the Global Health Catalyst has been research into cancer and non-communicable diseases, but in the last few years researchers at the center developed an interest in pain management, Asana said.
“That led to our initial dabbling with cannabinoids and their potential to be used to manage pain,” she said. “It just seemed like things were coming together and it was a great time to explore this.”
Access to pain medications is severely limited in poor and developing countries. For example, of the 329 tons of morphine-equivalent opioidsdistributed worldwide per year, roughly 22 pounds went to low-income countries, according to a report from the International Narcotics Control Board (INCB), which looked the average global distribution between 2010 and 2013. The INCB found in a 2015 report that 75% of the world population has no access to proper pain relief medicines.
A study in 2017 by the Lancet Commission on Pollution and Health showed that more than 25.5 million people who died in 2015experienced serious health-related suffering. Of those, more than 80% of the people who died with serious illnesses that year were from developing regions — and the vast majority lacked access to palliative care and pain relief. Each year, nearly 2.5 million children die with serious health-related suffering, 98% of whom are from developing regions, according to the Lancet report.
“This is a major problem in African countries and Southeast Asian countries,” Asana said.
Ngwa, who used the term “farm to bedside” to describe the breadth of their planned research, said the institute will begin looking at crops with the goal of clearing up the reams of existing, but confusing and conflicting, scientific information on cannabis.
“One of the things that we think is the problem is that each cannabis product, whether it's grown in California or it's grown in Massachusetts, is not the same,” Ngwa said.
Ngwa said the institute will operate in a Drug Enforcement Agency (DEA)-approved facility at the Harvard Institutes of Medicine and other Harvard facilities to provide quality assurance to their industry partners. They'll also begin studying the plant to develop uniform standards and applications.
“We provide high-quality, credible scientific analysis to identify what molecules are present and in what quantities, and can provide comparative analysis based on available data which would inform research conclusions, marketing, etc.,” he said.
The number of collaborators and industry partners represents an unprecedented level of collaboration at the Harvard-based institute.
IPI industry partners with either sponsored research agreements or commitments include Flavocure Biotech Inc.; Atlas Biotechnologies, and Cannabis Science Inc. Another partner is the Locker Room Consulting-Nestre-Primative (LNP) consortium.
Locker Room Consulting was founded by a group of professional athletes, including former National Football League (NFL) receiver Calvin Johnson, to help other former athletes in business and philanthropy.
The NFL and the NFL Players Association announced in May 2019 their plan to support additional resources for pain management in athletes, including alternative therapies such as cannabis.
Educational partners include the University of Pennsylvania, Oxford University in the United Kingdom, the University of Massachusetts, and the University of Heidelberg in Germany.
Though the institute just launched, and staffing and the focus of upcoming clinical trials are undetermined, Ngwa said he expects the institute to begin a clinical trial in 2020
Harvard is the United States' oldest institution of higher learning. Its history, influence, and wealth have made it one of the world's most prestigious universities.
The university is often cited as the world's top tertiary institution by most publishers.
Harvard's motto is "veritas" (TRUTH)
Maybe I get to meet Calvin Johnson and eat a justicia burger when I get my gift shares, sometime in the soon there after.
Seed funding for the program is being provided by Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, both based in Boston, as well as from industry participants.
Industry partners so far include Atlas, Flavocure Biotech of Baltimore, CANNABIS SCIENCE OF COLORADO SPRINGS, Colorado and the consortium Locker Room Consulting-Nestre-Primative.
partnership
Published 10 hours ago | By Matt Lamers
Harvard University is spearheading what participants are calling one of the largest international efforts for research on medical cannabis – and the school has chosen Alberta, Canada-based Atlas Biotechnologies as a founding partner of the initiative.
Atlas will initially be the sole supplier of marijuana and its derivatives for the research.
The new International Phytomedicines and Medical Cannabis Institute (IPI) – unveiled Sunday at the Global Health Catalyst – will be based at Harvard Medical School in Boston.
The university partnership with the private sector could validate certain treatments by proving the efficacy of formulations, ultimately making those treatments more marketable, according to participants in the program.
“If we can prove the efficacy, we will be tapping into an existing medical market but also opening up what I believe to be a very lucrative opportunity for business. But what we’re looking for primarily are less harmful treatments,” Atlas CEO Sheldon Croome told Marijuana Business Daily.
“We believe we’re on to a good market opportunity, but it’s a great opportunity for us to bring something that’s not toxic for the body to market – and hopefully help a lot of people without the risk of addiction and other issues.”
Seed funding for the program is being provided by Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, both based in Boston, as well as from industry participants.
Industry partners so far include Atlas, Flavocure Biotech of Baltimore, Cannabis Science of Colorado Springs, Colorado and the consortium Locker Room Consulting-Nestre-Primative.
Atlas has committed 3 million Canadian dollars ($2.2 million) to the research program.
As part of the collaboration, Atlas will supply cannabis products to Harvard Medical for use in trials from its cultivator subsidiary in Canada Atlas Growers – and potentially to other post-secondary institutions in the United States for research and development purposes.
The Canadian company’s research with Harvard will focus on neurological disorders and pain.
Any new intellectual property generated in those areas will be shared equally between the two parties.
“We, nor the director of Harvard Global Health Catalyst, have come across a group that involves a similar caliber of institutions and industry all striving together to achieve one goal,” Atlas Chief Operating Officer Jeffrey Gossain said. “By combining all these groups into one institute, we have created the best possible way to achieve unprecedented health and wealth from medicinal plants.
“If we can come out of it with really good indications on things that lead to alleviating some of the symptoms for those patients, that would be really beneficial.”
The first shipment of medical marijuana from Atlas is expected in July.
“As you kind of move forward, the more research that we have around cannabis, the more comfortable doctors will be prescribing cannabis derived products for all these different symptoms,” Gossain said.
“And that’s kind of the vision we have. To create the world’s most trusted cannabis products. And trust is going to be based on the research and development we do as a whole industry.”
Harvard’s partnership with Atlas involves funding over the next three years based on targeted research goals.
Croome called the collaboration “the most important institutional partnership in medical cannabis to date.”
“It is truly groundbreaking and exciting to have one of the world’s leading institutions doing clinical trials and efficacy studies on cannabis compounds,” he said.
Matt Lamers can be reached atmattl@mjbizdaily.com
Dabney and Megatron at Harvard this weekend?
I wonder what will come of this?
International Phytomedicines Institute for global health and development
Building on recent developments and advances in plant medicines products islolated from Justicia, cannabis, and other plants, the institute with main hub at Harvard Medical School will unveil and drive new scientific evidence and discovery elevating medicinal plants to the global health arena, benefiting healthcare and development in both HIC and LMIC. This initiative will complement the C4, designed to include partnerships with the Department of Botany of the Smithsonian Institute, UPS, and community leaders in LMIC.
At .0333 your gift was a dollar 9 years ago.
I did not expect mine until federal change.
2 more gifts since.
A lot has happened in the last 10 years
The original gift continues to grow.
The fruits of this plant will heal the nations once more.
Cannabis vs opioids
The plant of life vs the plant of feels good and then doomed.
The original message is simple.
History speaks for itself.
It's alright, ooh, it's alright, ooh
Yeah, come over here and sit next to me
We can see where things go naturally
Just say the word and I'll part the sea
Just come over here and sit next to me
And I'll take you high, high, high, high
It's alright
It's alright
Yeah, it's alright
Yeah, it's alright
Africa is BIG
The greatest story ever told, this story of this burning Bush.
Why would you not partake?
Good luck on your investments.
Opportunity to make amends.
Cannabis research is obvious.
An easy mistake to admit.
Who made the mistake anyway, it's was made long ago.
I hope we take this opportunity.
The original gift keeps on giving.
WHO Proposes Downgrading Cannabis Under International Law For First Time
HEALTH AND MEDICINE
The WHO has proposed to the UN that cannabis be downgraded under international law after reviewing scientific studies on the potential benefits of it. Yargin/Shutterstock
BY KATY EVANS
11 FEB 2019, 14:45
The World Health Organization (WHO) is proposing downgrading cannabis under international law for the first time, in light of growing evidence of its legitimate medicinal benefits.
Currently classified by the WHO (US classification is slightly different) as schedule IV – the same class as heroin – which is the most strictly controlled category, the WHO Expert Committee on Drug Dependence (ECDD) has proposed to reschedule cannabis, and other cannabis-related products as a schedule I classification. What’s more, they’ve proposed removing non-THC (the psychoactive component of cannabis) cannabis products, such as CBD oil, from international drug controls completely.
In November last year, the WHO’s ECDD met to carry out the first full review of cannabis and cannabis-related substances since it was first listed under the International Drug Control Conventions as schedule IV in 1961.
The WHO schedule categories, first implemented to categorize the potential health risks and benefits of specific substances, range from schedule I – substances with addictive properties and risk of abuse, to schedule IV, the most harmful of the schedule I substances, with the addition of having extremely limited medical or therapeutic value. Cannabis currently come under both.
The WHO is proposing to the United Nationsthat cannabis be deleted from schedule IV, and Tetrahydrocannabinol (THC), which is currently listed separately as scientists had not identified THC as the psychoactive component of cannabis in 1961, be downgraded to schedule I in light of mounting evidence of the potential for medicinal and therapeutic value.
“The Committee recognized the public health harms presented by these substances, as well as their potential for therapeutic and scientific use,” the WHO stated. “As a result, the Committee recommended a more rational system of international control surrounding cannabis and cannabis-related substances that would prevent drug-related harms whilst ensuring that cannabis-derived pharmaceutical preparations are available for medical use.”
They have also recommended that extracts and tinctures derived from cannabidiol (CBD), which doesn’t contain a psychoactive component, be removed completely from the scheduling, and thus not be restricted under international law.
The review is long overdue in the face of scientific research into the health benefits of the drug, which weren't available back in 1961. However, as research continues, attitudes have been changing towards cannabis and it is now legal for medical use in 30 countries around the world, including Canada, some parts of the US, Mexico, Germany, Denmark, Finland, Israel, Argentina, and Australia, with many more under review.
Studies have linked the medical use of cannabis with helping manage chronic pain, epilepsy, depression, and psychosis, and though it isn't a cure-all for cancer, it has been linked to helping patients deal with nausea caused by chemotherapy, amongst others. The new classification would allow for further scientific and medical research into the benefits of THC and CBD.
“These recommendations are of monumental importance as they may lead to the overcoming of barriers to research, enhance access of patients to cannabis-based medicine, and allow free commerce of cannabis products internationally,” Ethan Russo of the International Cannabis and Cannabinoids Institute told Newsweek.
The UN’s Commission on Narcotic Drugs will vote on the recommendation in March.
Senators Focus On Marijuana’s Role In Combating Opioid Crisis At Hearing
Published
7 hours ago
on
February 12, 2019
By
Kyle Jaeger
Doctors testifying about the opioid epidemic on Capitol Hill on Tuesday made clear that marijuana has medical potential as an alternative pain treatment option and that federal prohibition is inhibiting cannabis research.
The Senate Health, Education, Labor and Pensions Committee held a hearing to discuss how to manage the nation’s opioid crisis, and medical marijuana was a point of particular interest raised by several lawmakers.
Sen. Lamar Alexander (R-TN), who chairs the panel, asked Dr. Andrew Coop of the Maryland School of Pharmacy what he considered “the most promising, non-addictive painkiller treatments or medicines that are coming down the road.”
“The drugs that are coming—I mentioned cannabinoids,” Coop said. “I know that’s a controversial topic, but this is great—”
The senator cut in to ask why it was controversial and Coop said it was because cannabis remains federally illegal. He clarified for Alexander that he was referring to “medical marijuana” when he brought up cannabinoids.
“Medical marijuana, yes,” Coop said. “I think that has great potential.”
Sen. Mitt Romney (R-UT) later said that while he didn’t have time during his allotted five minutes to ask about marijuana, he wanted Coop to “instruct us as to the path forward on cannabis research.”
The next senator to bring up cannabis was Sen. Jacky Rosen (D-NV). She said her state’s medical marijuana program “has reduced the prescriptions for high-potency painkillers” and asked Coop whether cannabis could serve as “a non-addictive approach or alternative to chronic pain—just another tool in the toolbox.”
“I, first of all, think it has great potential to be another tool in the toolbox,” he said. However, “I don’t think there’s ever going to be a one-size-fits-all magic bullet because pain is different in different people.”
“In terms of how to move the research forward in medical marijuana, one of the issues has been because of the usual legal status in the United States, research has been limited,” he said. “There’s no consistency between the different types of marijuana, the studies done. We need good, consistent, well-designed clinical studies with good, consistent material so that we can fully assess the impact, and don’t get me wrong, also the potential drawbacks.”
David Mangone, director of government affairs for the advocacy group Americans for Safe Access, said in a press release that it was “great to see witnesses and senators alike discuss the potential of medical cannabis as a tool in combating the opioid crisis,” but that “we need real action from from our lawmakers to change federal laws.”
Sen. Doug Jones (D-AL) was the last to raise marijuana at the hearing. He emphasized that while lawmakers sometimes approach their questioning in hearings with an agenda in mind, “this is not one of those” situations. He wanted to hear from the three other witnesses who hadn’t testified on the topic.
Cheryl Steinberg, national director of policy and advocate at the U.S. Pain Foundation, said “cannabis has helped a number of people living with pain” and that it’s “another option” in the toolbox for pain patients. She stressed that marijuana’s legal status make it hard to standardize cannabis treatment.
“Doctors need to be the one prescribing it, but they don’t know what they’re doing with it,” she said. “They’re not trained with it either. Without having a really good research base, we’re just flying blind.”
So what’s preventing that research, Jones asked?
“The fact that it’s not legal,” Steinberg said.
While Mayo Clinic physician Halena Gazelka said she wasn’t convinced that cannabis isn’t addictive, she agreed that “the impediment has been that it’s a Schedule I substance and it’s not permissibly prescribed by providers.”
“But I do think that there may be some significant areas where this may be very useful,” she said. “I have some palliative medicine patients using it for nausea, appetite, pain, and I think it can be helpful.”
Finally, Anuradha Rao-Patel, a physician representing the health insurance company Blue Cross Blue Shield of North Carolina, said “the limitations such as the fact that it is illegal in some states as well as on a federal level makes research [on marijuana] difficult.”
“From a physician’s standpoint, I think there is some potential to the utility of medical marijuana for the treatment of chronic pain,” she said. “I’ll say, putting on my other hat as an insurer, that we obviously only cover procedures and drugs that are [Food and Drug Administration]-approved, so we would obviously need some clinical evidence and support to be able to cover these kinds of medications.”
Don Murphy, director of federal policies at the Marijuana Policy Project, told Marijuana Moment that the “questions from senators proved there is a need for a hearing devoted exclusively to cannabis as an alternative to opioids.”
“
Of course, such a hearing may expose a truth some of them don’t want to hear,” he said.
WHO will unlock the Gates?
The fruits of this plant will heal the nations once more.
Can I get an eblast?
Metered dose, medical device.
Sounds good.
The gift that keeps on giving.
Metered dose, medical device.
THC smoke and vapor free, nano technology.
Real terpenes and other fruits distributed.
And Georgie just gave it away?
It's was fun for a moment.
Do you think there will be news soon for shareholders? Or forever left in the dark.